Objective To assess the efficacy and safety of paclitaxel, ifosfamide and cisplatin (TIP) as the first-line treatment for the patients with intermediate- or poor-risk testicular cancer retrospectively. Methods Patients with intermediate- or poor-risk testicular cancer in our center received TIP as the first-line treatment. Objective response rate, 2-year progression free survival(PFS) and overall survival(OS) were evaluated. Results The mean treatment of 20 patients was 4.25cycles. Six patients achieved CR(30%), seven patients had partial response(35%) and overall response rate was 65%. The median follow-up time was 25 months. Three patients died of tumor progression. Hematologic toxicity was most common(95%), with 30% of grade 3-4 neutropenia. Estimated 2-year PFS was 72.9% and OS was 89.1%. Conclusion Paclitaxel, ifosfamide and cisplatin(TIP) are safe and effective as the first-line treatment on patients with intermediate- or poor-risk testicular cancer. Compared with previous studies, 2-year PFS and OS have been improved. Adverse effect could be controlled. Further researches are still needed.